BiotechTube

BA3182

Phase 1Recruiting
0 watching 0 views this week💤 Quiet
25
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Advanced Adenocarcinoma

Conditions

Advanced Adenocarcinoma

Trial Timeline

Jul 14, 2023 → Sep 15, 2028

NCT ID
NCT05808634

About BA3182

BA3182 is a phase 1 stage product being developed by BioAtla for Advanced Adenocarcinoma. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05808634. Target conditions include Advanced Adenocarcinoma.

Hype Score Breakdown

Clinical
10
Activity
5
Company
2
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT05808634Phase 1Recruiting

Competing Products

20 competing products in Advanced Adenocarcinoma

See all competitors
ProductCompanyStageHype Score
AK-105AkesoPhase 1
32
AFM24 + Atezolizumab 840 MG in 14 ML InjectionAffimedPhase 1/2
33
EXS21546BiotrialPhase 1/2
33
SY-1365 (Part 1) + Carboplatin + Fulvestrant + SY-1365 (Cohort 2) + SY-1365 (Cohort 5) + SY-1365 (Part 2 Single Agent)Syros PharmaceuticalsPhase 1
25
Necitumumab + Gemcitabine + CarboplatinEli LillyPhase 2
52
Pemetrexed + Erlotinib + Pemetrexed + ErlotinibEli LillyPhase 2
52
NBTXR3NanobiotixPhase 1/2
36
pegfilgrastim + LY2523355Eli LillyPhase 1
33
SON-1010Sonnet BioTherapeuticsPhase 1
28
SON-1010Sonnet BioTherapeuticsPhase 1/2
36
BT1718Bicycle TherapeuticsPhase 1/2
33
Zentalis + GemzarZentalis PharmaceuticalsPhase 2
44
IMC-18F1Eli LillyPhase 1
33
Tadalafil + GemcitabineEli LillyPhase 1
33
OKI-179OnKure TherapeuticsPhase 1
25
OKI-219 + Fulvestrant + Trastuzumab + Tucatinib + Atirmociclib + RibociclibOnKure TherapeuticsPhase 1
25
LY3499446 + Abemaciclib + Cetuximab + Erlotinib + DocetaxelEli LillyPhase 1/2
41
LY3434172Eli LillyPhase 1
33
ACR-2316Acrivon TherapeuticsPhase 1
25
BBP-398LianBioPhase 1
25

Other Products from BioAtla

CAB-AXL-ADC + PD-1 inhibitorPhase 2
44
Ozuriftamab Vedotin + Pembrolizumab + Evalstotug (BA3071) + CetuximabPhase 2
44
Durvalumab + BA3011 + BA3021 + ENB003 + ToripalimabPhase 2
44
CAB-AXL-ADC + PD-1 inhibitorPhase 1/2
33
BA3071 + Nivolumab + Pembrolizumab + Pemetrexed (Alimta)Phase 1/2
33